| Half life in dog at 3 mg/kg, po - BioAssay Summary Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented. ..more |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||
Tested Compound: Description: Title: Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist. Abstract: Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented. (PMID: 21658961) Comment Putative Target: ChEMBL Target ID: 50588 Target Type: ORGANISM Pref Name: Canis familiaris Organism: Canis lupus familiaris Tax ID: 9615 Confidence: Target assigned is non-molecular Relationship Type: Non-molecular target assigned Categorized Comment ChEMBL Assay Type: ADMET ChEMBL Assay Data Source: Scientific Literature ChEMBL Assay Test Type: In vivo Result Definitions
Data Table (Concise)
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||